Brief: Painreform Commences Development For Ocuring™-K Phase II Trial
02/12/2025 14:19
Dec 2 (Reuters) - PainReform Ltd PRFX.O: PAINREFORM COMMENCES DEVELOPMENT FOR OCURING™-K PHASE II TRIAL, LAYERBIO’S DROP-LESS SUSTAINED-RELEASE OCULAR THERAPY Source text: ID:nGNX2yr8dv Further company coverage: PRFX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on PRF Technologies
See all newsBrief: Prf Technologies S.H.N. Financial Investments Seeks Special General Meeting At Prf Technologies To Remove Directors, Appoint Three S.H.N. Nominees
U.S. STOCKS ON THE MOVE-Bumble, Tempus AI, TD Synnex
U.S. STOCKS ON THE MOVE-Bio-Techne, IBM, Apple
PRF Technologies rises as animal study shows pain drug matches approved rival
U.S. STOCKS ON THE MOVE-Wendy's, Canadian Solar, Bio-Techne